Neos Therapeutics, Inc. (NEOS)

[chainma1l]

They probably have enough for 2017, but they will need more at some point and a secondary is PROBABLY the best way to go about it. Sucks, but that's the reality. But even with another 10 million shares (just a guess), the OS and float are going to be tiny. I don't know why they couldn't do a private placement for the whole amount, but typically it's just a big open market sale.
I think the company's future is very bright, but they will need to get some cash before they hit the break even point with their products--which hopefully is very soon.
The growth of Adzenys has been incredible and Cotempla should be very similar just because it's a different drug for the same problem and I'm sure doctors who can't prescribe Adzenys for one reason or another will prescribe Cotempla. And another PDUFA in September. Should be a great year overall, just a bothersome few weeks here.
Good luck to you!